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The present special issue addresses two key areas, which at
first sight may not appear to be particularly related to each
other. Their novelty, however, connects them tightly. The
appearance of these two issues has, on one hand, required and
promoted a renewal of the perspective in addiction science
and, on the other hand, could facilitate the rethinking of prac-
tical, therapeutic, and preventive interventions. Thus, both
areas share a main common aspect: they raise new issues that
need to be addressed in the field of addictions and, as such,
force us to reconsider former approaches.
One of the focuses is the emergence of novel psychoactive
substances, especially in relation to the fast moving and the
potentially unlimited nature of their online market [1]. A
“novel psychoactive substance” has been legally defined by
the European Union as a new narcotic or psychotropic drug,
either in pure form or in a preparation, that is not scheduled
under the Single Convention onNarcotic Drugs of 1961 or the
Convention on Psychotropic Substances of 1971, but which
may pose a public health threat comparable to substances
listed in the above-mentioned conventions (Council of the
European Union decision 2005/387/JHA) (UNODC, 2014).
From the psychedelic movements of the 1960s until the
beginning of the 21st century, there was hardly any change
regarding the most used drugs. In addition to cannabis,
heroin, and cocaine, primarily LSD and, to a lesser extent,
magic mushrooms among hallucinogenic drugs and amphet-
amine basically covered the significant range of substances of
abuse. Although the presence of ecstasy from the end of the
1980s had brought some moderate changes, it can be stated
that researchers and prevention and treatment professionals
could work in a relatively stable environment throughout
decades. Users basically used the same drugs and sought help
for similar problems, and therefore studies could systemati-
cally grow and support the preventive and clinical efforts.
The novel psychoactive substances, however, that began
to spread after the millennium [2–4] have fundamentally
reorganized this apparently stable situation. Since then, new
substances have constantly been appearing on the market. It
is not rare that there is no time to even identify a new drug
before another substance takes its place on the market and
theymight disappear a few days, weeks, ormonths later, while
newer ones appear.This extremely rapidly changing situation
concerning drug use and drug market set new challenges for
professionals. We have to describe the use of drugs on which
we have very limited knowledge. Not only is the chemical
description of these substances often unavailable, but often
we do not even know their street names. The effects of drugs
should be exploredwhile their name and nature are unknown
to both the dealer and the user. We have to estimate the risks
associated with substances without being familiar even with
their most basic characteristics. We have to provide informa-
tion to potential users of these drugs and we hardly know
anything about them or treat unknown side effects or over-
doses.
It is no surprise that in this rapidly changing environment
initiatives have been launched [5] that apply new data
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collection methods and aim to gather information as fast
as possible and share this knowledge within target groups
via new effective tools [2, 3]. The opportunities provided
by the developments in the field of info communication
technologies, the Internet, and smartphones could be of great
value for this aspect. All these factors, in fact, contribute to the
rethinking and renewal of data collection and data analysis
methods, the reallocation of resources, and the reconsidera-
tion of prevention tools and efforts, aswell as the implementa-
tion of other types of interventions.The present special issue,
on one hand, intends to make a contribution for facing these
challenges.
On the other hand, during the past few years, “new
addictions” have emerged in addition to the new drugs.These
addictions are actually not a new problem of course, but the
formerly described disorders appear in a new interpretative
framework. In the past decades, but especially in the past few
years, the opinion that the range of addictive disorders should
not be reduced to psychoactive substances-related dependen-
cies has been strengthened. In line with this, scientific litera-
ture on addictions has begun to deal with a growing number
of phenomena, originally not classified as addictive disorders,
but with important psychological and social consequences
[6–8].
Among behavioral addictions gambling disorder repre-
sents the main area, giving the large diffusion of gambling.
With the increase in availability of gambling products across
the world and the increased exposure to gambling advertise-
ments both on TV and on mobile platforms, we are currently
faced with a larger number of people across the globe who are
using gambling as a recreational pursuit.
Issues of current significance in the gambling world are
the targeting of children and adolescents by the gambling
industry, the targeting of older people by larger casinos offer-
ing company and distraction but focusing on a vulnerable
group, and the targeting of female and indigenous popula-
tions, who are being reached by specific advertising cam-
paigns across most of the world.
Besides the new interpretation of gambling disorder,
formerly classified as an impulse control disorder, new inter-
pretations of numerous other disorders from the addiction
perspective have also been raised. Among these are other
impulse control disorders, eating disorders, specific sexual
disorders, and, among other problems officially not classified
as disorders, the Internet addiction, online gaming, exercise
addiction, and many others. It is becoming more and more
common to see the expressions of behavioral addiction or
nonsubstance use addiction [9, 10]. The formal expansion of
the range of addictive disorders to the direction of addic-
tions not related to chemical substances has eventually been
brought by the publishing of DSM-5 [11]. In this edition of the
manual, the former section on “Substance-Related Disorders”
has been replaced with “Substance-Related and Addic-
tive Disorders.” This chapter indeed includes a subchapter
titled “Non-Substance-RelatedDisorders.” Although addiction
experts could classify several disorders belonging here, at the
moment the only official member of this group is gambling
disorder. This modification, however, is of great symbolic
significance: it clearly represents the shift towards a new
perspective inwhich the presence of a psychoactive substance
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